Mersana faces the inevitable
Emilta-L continues to show worse efficacy than a rival ADC discontinued by Pfizer.
Enliven seeks its reverse merger payday
Early data with ELVN-001 hold up well against olverembatinib and TERN-701.
Another TIGIT bites the dust
GSK and iTeos dump belrestotug, with the latter now looking at “strategic alternatives”.
CytomX's EpCAM pivot does the job
After earlier masked probody setbacks, CytomX surprises with CX-2051.
Like Crest, Potomac succeeds up to a point
Imfinzi hits on disease-free survival, but BCG won't be displaced.
Takeda says no to B7-H3
TAK-280 is among the group's discarded projects, although it’s a T-cell engager, not an ADC.
